<p>防禦性行業，如醫療保健，對收入投資者更具吸引力。這是因為該行業的公司在經濟困難時期不太可能遭受重大業務中斷，這意味着它們也不太可能削減分紅。醫療需求與許多技術產品或服務不同，並不是可選的。果然，醫療保健行業擁有許多優秀的分紅股票。讓我們考慮兩個可能為其股東帶來終身回報（或更長時間）的公司：<strong>默克</strong>（MRK -0.43%）和 <strong>美敦力</strong>（MDT 0.92%）。</p>
<h2>1. 默克</h2>
<p>默克今年的表現不佳：公司的股價下跌了 4%。製藥公司表現不佳的一個原因是投資者擔心默克著名的癌症藥物 Keytruda 可能面臨競爭，而這款藥物無疑是其最大的增長驅動力。<strong>Summit Therapeutics</strong> 是一家臨牀階段的生物技術公司，正在開發一種名為 ivonescimab 的藥物，可能在非小細胞肺癌（NSCLC）這一關鍵市場與 Keytruda 競爭。</p>
<p>此外，Keytruda 將在 2028 年失去在美國的專利獨佔權，屆時將面臨仿製藥競爭。儘管如此，即使 ivonescimab 在此之前上市，Keytruda 的收入在 2028 年前仍應繼續增長。美國食品藥品監督管理局（FDA）已批准該藥物用於多個適應症，而 ivonescimab 在 2028 年前大多數適應症上不會觸及。默克還在研發該藥物的皮下給藥版本。該配方在 2028 年不會失去獨佔權，並且應該會取得一定的成功。</p>
<p>默克面臨的逆風是製藥公司常見的情況。這家醫療保健領導者能夠生存並蓬勃發展數十年，正是因為其開發新藥的能力。這是抵禦競爭的最佳防禦。而在這方面，默克仍應表現出色。公司的研發管線包含數十個項目。由於收購，默克還在擴展其管線。最近批准的 Winrevair，一種用於肺動脈高壓的藥物，源於對 Acceleron Pharma 的收購。</p>
<p>默克還與多家小型公司簽訂了多項合作協議，包括與 <strong>Moderna</strong> 合作開發個性化癌症疫苗。關鍵在於：過於關注與 Keytruda 相關的問題可能會導致投資者忽視整體情況。默克的道路上總會有逆風，但使公司能夠持續發展的因素依然存在。該公司也有着穩健的分紅記錄。在過去十年中，其分紅增加了 71%，目前提供的前瞻性收益率為 2.96%，高於 <strong>標準普爾 500</strong> 的平均水平 1.32%。</p>
<p>默克仍然是一個可靠的收入股票，值得持有。</p>
<h2>2. 美敦力</h2>
<p>美敦力是一家醫療設備專家，擁有罕見的分紅記錄。該公司連續 47 年增加分紅。能夠做到這一點需要強大的業務，而美敦力正是如此。它在多個類別中擁有數十種產品，並在全球 100 多個國家運營。這並不保證美敦力的表現特別好，但該公司有幾個令人興奮的長期機會。</p>
<p>其中一個機會在於其糖尿病護理部門，最近成為其最大的增長驅動力。美敦力在該領域的創新包括 MiniMed 780G，這是唯一一款具有餐食檢測技術的胰島素泵（它會根據患者的需求自動調整胰島素水平）。全球有五億成年人受到糖尿病的影響，因此迫切需要美敦力開發的這類產品。美敦力還在開發一種機器人輔助手術設備 Hugo 系統，這可能成為一個重要的長期推動力。</p>
<p><strong>Intuitive Surgical</strong> 主導着這個市場，但考慮到全球老齡化人口以及這將對醫療系統造成的需求增加，微創手術機器人系統將變得越來越重要。這些手術通常比開放手術切口更小，因此造成的傷疤和出血更少，恢復時間和住院時間也更短。Hugo 系統目前正在美國進行臨牀試驗。</p>
<p>美敦力在最近幾個季度的收入增長方面遇到了一些困難。然而，從長遠來看，這家醫療巨頭應該會恢復。美敦力應該會在幾年內成為分紅之王，並在此後繼續增加分紅。</p>

默克

<p>本文討論了兩隻推薦用於長期被動收入的股息股票：默克和美敦力。儘管默克在其癌症藥物 Keytruda 方面面臨競爭，但其產品線強勁，過去十年股息增長了 71%。美敦力以其醫療設備而聞名，已連續 47 年提高股息，並專注於糖尿病護理和機器人輔助手術的增長。這兩家公司在醫療保健行業的定位良好，使其對收入投資者具有吸引力</p>

<p>Defensive industries, like healthcare, are more attractive to income investors. That's because companies in this sector are less likely to suffer significant business disruptions in times of economic trouble, meaning they are also less likely to cut their payouts. Medical needs, unlike many technological products or services, aren't optional. Sure enough, the healthcare industry is home to many excellent dividend stocks. Let's consider two that could reward their shareholders for a lifetime (or more): <strong>Merck</strong>(MRK -0.43%) and <strong>Medtronic</strong>(MDT 0.92%).</p>
<div class="lb-trans"><p>防禦性行業，如醫療保健，對收入投資者更具吸引力。這是因為該行業的公司在經濟困難時期不太可能遭受重大業務中斷，這意味着它們也不太可能削減分紅。醫療需求與許多技術產品或服務不同，並不是可選的。果然，醫療保健行業擁有許多優秀的分紅股票。讓我們考慮兩個可能為其股東帶來終身回報（或更長時間）的公司：<strong>默克</strong>（MRK -0.43%）和 <strong>美敦力</strong>（MDT 0.92%）。</p>
</div><h2>1. Merck</h2>
<div class="lb-trans"><h2>1. 默克</h2>
</div><p>Merck isn't having a good year: The company's shares are down by 4%. One reason behind the drugmaker's poor performance is that investors are worried about potential competition for Keytruda, Merck's famous cancer drug, which is by far its biggest growth driver. <strong>Summit Therapeutics</strong>, a clinical-stage biotech, has a medicine in development called ivonescimab that could rival Keytruda in non-small cell lung cancer (NSCLC), one of its key markets.</p>
<div class="lb-trans"><p>默克今年的表現不佳：公司的股價下跌了 4%。製藥公司表現不佳的一個原因是投資者擔心默克著名的癌症藥物 Keytruda 可能面臨競爭，而這款藥物無疑是其最大的增長驅動力。<strong>Summit Therapeutics</strong> 是一家臨牀階段的生物技術公司，正在開發一種名為 ivonescimab 的藥物，可能在非小細胞肺癌（NSCLC）這一關鍵市場與 Keytruda 競爭。</p>
</div><p>Furthermore, Keytruda will lose patent exclusivity in the U.S. in 2028 and then face generic competition. That said, Keytruda's revenue should continue growing until 2028 even if ivonescimab hits the market before. The Food and Drug Administration (FDA) has approved the medicine across scores of indications, most of which ivonescimab won't touch before 2028. Merck is also working on a subcutaneous version of the drug. This formulation won't lose exclusivity in 2028 and should be somewhat successful.</p>
<div class="lb-trans"><p>此外，Keytruda 將在 2028 年失去在美國的專利獨佔權，屆時將面臨仿製藥競爭。儘管如此，即使 ivonescimab 在此之前上市，Keytruda 的收入在 2028 年前仍應繼續增長。美國食品藥品監督管理局（FDA）已批准該藥物用於多個適應症，而 ivonescimab 在 2028 年前大多數適應症上不會觸及。默克還在研發該藥物的皮下給藥版本。該配方在 2028 年不會失去獨佔權，並且應該會取得一定的成功。</p>
</div><p>Headwinds, such as the ones Merck is facing, are typical for pharmaceutical companies. The healthcare leader has survived and thrived for decades because of its ability to develop new medicines. That's the best defense against competition. And in that department, Merck should still excel. The company's pipeline features several dozen programs. It is also expanding it thanks to acquisitions. Its most-recent, brand-new approval of Winrevair, a medicine for pulmonary arterial hypertension, stemmed from the acquisition of Acceleron Pharma.</p>
<div class="lb-trans"><p>默克面臨的逆風是製藥公司常見的情況。這家醫療保健領導者能夠生存並蓬勃發展數十年，正是因為其開發新藥的能力。這是抵禦競爭的最佳防禦。而在這方面，默克仍應表現出色。公司的研發管線包含數十個項目。由於收購，默克還在擴展其管線。最近批准的 Winrevair，一種用於肺動脈高壓的藥物，源於對 Acceleron Pharma 的收購。</p>
</div><p>Merck also has several collaboration agreements with smaller companies, including <strong>Moderna</strong>, with which it is developing a personalized cancer vaccine. Here's the point: Focusing too much on Keytruda-related issues might cause investors to miss the forest from the trees. There will always be headwinds in Merck's way, but the things that have allowed the company to last as long as it has remained intact. The company also has a solid dividend record. Its payouts have increased by 71% in the past decade, and it currently offers a forward yield of 2.96%, higher than the <strong>S&amp;P 500</strong>'s average of 1.32%.</p>
<div class="lb-trans"><p>默克還與多家小型公司簽訂了多項合作協議，包括與 <strong>Moderna</strong> 合作開發個性化癌症疫苗。關鍵在於：過於關注與 Keytruda 相關的問題可能會導致投資者忽視整體情況。默克的道路上總會有逆風，但使公司能夠持續發展的因素依然存在。該公司也有着穩健的分紅記錄。在過去十年中，其分紅增加了 71%，目前提供的前瞻性收益率為 2.96%，高於 <strong>標準普爾 500</strong> 的平均水平 1.32%。</p>
</div><p>Merck remains a reliable income stock to hold onto for good.</p>
<div class="lb-trans"><p>默克仍然是一個可靠的收入股票，值得持有。</p>
</div><h2>2. Medtronic</h2>
<div class="lb-trans"><h2>2. 美敦力</h2>
</div><p>Medtronic, a medical-device specialist, has a rare dividend streak. The company has increased its payouts for 47 consecutive years. It takes a strong business to pull that off, and that's what Medtronic has. It boasts dozens of products across several categories and operates in more than 100 countries worldwide. That doesn't guarantee that Medtronic will perform particularly well, but the company has several exciting long-term opportunities.</p>
<div class="lb-trans"><p>美敦力是一家醫療設備專家，擁有罕見的分紅記錄。該公司連續 47 年增加分紅。能夠做到這一點需要強大的業務，而美敦力正是如此。它在多個類別中擁有數十種產品，並在全球 100 多個國家運營。這並不保證美敦力的表現特別好，但該公司有幾個令人興奮的長期機會。</p>
</div><p>One is within its diabetes care segment, which has been its biggest growth driver lately. Medtronic's innovations in the field include its MiniMed 780G, the only insulin pump with meal-detection technology (it automatically adjusts insulin levels based on patients' needs). With diabetes affecting half a billion adults worldwide, there is a dire need for precisely the kinds of products Medtronic develops. Medtronic is also developing a robotic-assisted surgery device, the Hugo system, that could prove to be an important long-term tailwind.</p>
<div class="lb-trans"><p>其中一個機會在於其糖尿病護理部門，最近成為其最大的增長驅動力。美敦力在該領域的創新包括 MiniMed 780G，這是唯一一款具有餐食檢測技術的胰島素泵（它會根據患者的需求自動調整胰島素水平）。全球有五億成年人受到糖尿病的影響，因此迫切需要美敦力開發的這類產品。美敦力還在開發一種機器人輔助手術設備 Hugo 系統，這可能成為一個重要的長期推動力。</p>
</div><p><strong>Intuitive Surgical</strong> dominates this market, but given the world's aging population and the increased demand that will place on health systems, the minimally invasive surgeries robot systems allow physicians to perform should become increasingly important. They typically involve less cutting off the skin than open surgeries, and hence less scaring and less bleeding, and shorter recovery times and hospital stays. The Hugo system is currently undergoing clinical trials in the U.S.</p>
<div class="lb-trans"><p><strong>Intuitive Surgical</strong> 主導着這個市場，但考慮到全球老齡化人口以及這將對醫療系統造成的需求增加，微創手術機器人系統將變得越來越重要。這些手術通常比開放手術切口更小，因此造成的傷疤和出血更少，恢復時間和住院時間也更短。Hugo 系統目前正在美國進行臨牀試驗。</p>
</div><p>Medtronic has had some trouble growing its revenue at a good clip in recent quarters. However, over the long run, the healthcare giant should recover. Medtronic should become a Dividend King within a few years and continue growing its payouts long after.</p>
<div class="lb-trans"><p>美敦力在最近幾個季度的收入增長方面遇到了一些困難。然而，從長遠來看，這家醫療巨頭應該會恢復。美敦力應該會在幾年內成為分紅之王，並在此後繼續增加分紅。</p>
</div>

兩隻適合終身被動收入的股息股票